Stanford Researchers Identify Potential Alzheimer's Disease Biomarker 15 Years Before Symptom Onset
• Stanford University neuroscientists discovered a blood-based biomarker (phosphorylated tau-217) that reliably predicts Alzheimer's disease development one to two decades before cognitive decline appears, according to research published April 20. • The biomarker was identified through analysis of blood samples from 2,500 cognitively healthy individuals followed for 15 years, with positive predictive value exceeding 92% in early-stage detection. • The finding could enable preventative therapies targeting amyloid and tau proteins before neurodegeneration becomes irreversible, potentially transforming Alzheimer's treatment approaches.
news.stanford.edu